A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) (NCT06174987)
A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
🩺 Plain-English Summary (8th-Grade Level)
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
Who can join: Review the eligibility criteria below.
Location: Miami Cancer Institute — Miami, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- Miami Cancer Institute — Miami, Florida
- Duke University - Trent Center — Durham, North Carolina
- Flinders Medical Center — Bedford Park,
- Monash Medical Center — Melbourne,
- Grand Hôpital de Charleroi — Charleroi,
- Instituto Aericas — Rio de Janeiro,
- A.C. Camargo Cancer Center — São Paulo,
- IBCC Nucleo de Pequisa e Ensino — São Paulo,
- Institut Gustave Roussy — Villejuif,
- Rabin Medical Center — Petah Tikva,
- Ospedale San Raffaele — Milan,
- Istituto Nazionale Tumori Fondazione G. Pascale — Naples,
- National Cancer Center Hospital — Chūō,
- Kyungpook National University Chilgok Hospital — Daegu,
- National Cancer Center — Gyeonggi-do,
- Seoul National University Bundang Hospital — Gyeonggi-do,
- Seoul National University Hospital — Jongno-gu,
- Severance Hospital, Yonsei University — Seoul,
- Asan Medical Center — Seoul,
- Samsung Medical Center — Seoul,
- Complejo Hospitalario Universitario A Coruña — A Coruña,
- Hospital Universitari Vall d'Hebron — Barcelona,
- Hospital Universitari Dexeus — Distrito de Les Corts,
- ICO l'Hospitalet - Hospital Duran i Reynals — L'Hospitalet de Llobregat,
- Hospital Ruber Internacional — Madrid,
📞 Contact the Study Coordinator
Phone: (908) 992-6400
Email: CTRinfo@dsi.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Cancer
- Intrapleural Catheter Daily Versus Three Times a Week Drainage — Houston, Texas
- Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer — Toronto, Ontario
- Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer — New York, New York
- FS120 Phase 1/1b Study in Patients With Advanced Malignancies — New Haven, Connecticut
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer — Encinitas, California
- Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) — Santa Rosa, California
Explore by condition: All Advanced Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.